Changes in estrogen production levels and exposure during aging may be contributing to the development of Alzheimer’s disease in women. And keeping their estrogen levels elevated with hormone therapy could improve brain health and reduce dementia risk, according to a new study.
Women are “disproportionately affected by Alzheimer’s disease (AD), a vulnerability that may relate to estrogen fluctuations across the lifespan,” said a study in the journal Neurology. Estrogen has “neuroprotective and vasoprotective effects,” suggesting that steady lifetime exposure may benefit “both AD-related neurodegeneration and cerebrovascular health.”
Researchers conducted MRIs on 352 healthy Swedish women at age 70 and again at age 75. Their study discovered that those with longer reproductive spans, the time between the first menstruation and menopause, showed less damage to the brain’s “tiny blood vessels” and “better-preserved white matter, the tissue that allows different parts of the brain to communicate,” said The Washington Post. “Data on hormone use were self-reported,” though, and there was a “lack of detailed information” about “when treatment began, the dose and the type of treatment,” the Karolinska Institute said in a news release.
Despite the correlation between estrogen and brain health, the study does not prove that estrogen or hormone therapy caused those differences. “Other hormones, which also fluctuate with menopause,” may be “contributing to the associations,” said ScienceAlert. Also, it’s unclear whether these “trends would apply to broader populations.” The study, though, “adds a new piece of evidence to a much broader reassessment of hormone therapy,” a “treatment whose risks and benefits have been fiercely debated for more than two decades,” said the Post.
|